Los Angeles Capital Management LLC Raises Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Los Angeles Capital Management LLC boosted its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 28.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,505 shares of the medical instruments supplier’s stock after acquiring an additional 4,960 shares during the quarter. Los Angeles Capital Management LLC owned 0.10% of LeMaitre Vascular worth $1,493,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Exchange Traded Concepts LLC boosted its holdings in LeMaitre Vascular by 0.8% during the 4th quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock valued at $1,343,000 after acquiring an additional 187 shares during the period. Riverwater Partners LLC boosted its holdings in LeMaitre Vascular by 2.5% during the 4th quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 198 shares during the period. Personal CFO Solutions LLC boosted its holdings in LeMaitre Vascular by 6.4% during the 4th quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock valued at $316,000 after acquiring an additional 336 shares during the period. Swiss National Bank raised its position in LeMaitre Vascular by 1.2% during the 3rd quarter. Swiss National Bank now owns 43,900 shares of the medical instruments supplier’s stock valued at $2,392,000 after purchasing an additional 500 shares during the last quarter. Finally, SRS Capital Advisors Inc. raised its position in LeMaitre Vascular by 325.5% during the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 524 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on LMAT shares. JMP Securities upped their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Roth Capital raised LeMaitre Vascular to a “strong-buy” rating in a research report on Friday, May 31st. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Barrington Research upped their price target on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and upped their price target for the company from $59.00 to $75.00 in a research report on Friday, April 26th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.57.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the sale, the chief executive officer now directly owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the sale, the chief executive officer now directly owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO George W. Lemaitre sold 8,000 shares of the stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total value of $602,400.00. Following the sale, the chief executive officer now owns 2,079,128 shares in the company, valued at $156,558,338.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 87,431 shares of company stock worth $6,627,520. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Up 1.1 %

LMAT stock opened at $81.50 on Friday. LeMaitre Vascular, Inc. has a twelve month low of $44.27 and a twelve month high of $84.15. The firm has a market cap of $1.83 billion, a PE ratio of 53.97, a price-to-earnings-growth ratio of 2.46 and a beta of 0.89. The business has a 50 day moving average of $74.63 and a 200 day moving average of $65.69.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. During the same quarter last year, the company earned $0.27 EPS. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.79%. LeMaitre Vascular’s dividend payout ratio is 42.38%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.